Last reviewed · How we verify
Contrast-Enhanced Ultrasound using Lumason
Lumason is a microbubble contrast agent that enhances ultrasound imaging by reflecting sound waves, improving visualization of blood flow and tissue perfusion.
Lumason is a microbubble contrast agent that enhances ultrasound imaging by reflecting sound waves, improving visualization of blood flow and tissue perfusion. Used for Contrast-enhanced ultrasound imaging for left ventricular opacification and endocardial border definition, Hepatic lesion characterization and detection, Pediatric cardiac and abdominal imaging.
At a glance
| Generic name | Contrast-Enhanced Ultrasound using Lumason |
|---|---|
| Also known as | SonoVue (25 mg under sulfur hexafluoride gas) / Lumason, Sulfur hexafluoride microbubbles for injection, US Patent No. 5,686,060 |
| Sponsor | Children's Hospital of Philadelphia |
| Drug class | Ultrasound contrast agent |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Lumason consists of sulfur hexafluoride microbubbles stabilized by a lipid shell. When injected intravenously, these microbubbles circulate through the vasculature and strongly reflect ultrasound waves, creating enhanced contrast in real-time imaging. This allows clinicians to better visualize perfusion patterns, detect abnormalities in blood flow, and improve diagnostic accuracy in cardiac, hepatic, and other organ imaging.
Approved indications
- Contrast-enhanced ultrasound imaging for left ventricular opacification and endocardial border definition
- Hepatic lesion characterization and detection
- Pediatric cardiac and abdominal imaging
Common side effects
- Headache
- Nausea
- Flushing
- Chest discomfort
- Hypersensitivity reactions
Key clinical trials
- CEUS Evaluation of Hydrocephalus in Neonates and Infants (PHASE2)
- Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses (PHASE1)
- Effectiveness of Contrast-Enhanced Ultrasound (PHASE4)
- Contrast-Enhanced Ultrasound for Kidney Transplant (PHASE1)
- Y-90 Treatment Response Using Transarterial Radioembolization (PHASE2)
- Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy (NA)
- CEUS Evaluation of Hypoxic Ischemic Injury (PHASE3)
- Intraoperative Contrast-Enhanced Ultrasound Evaluation of Blood Flow at the Time of Surgical Hip Reduction for DDH (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: